Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
Other Sizes |
|
Purity: ≥98%
Betamethasone (also called NSC-39470; SCH-4831; NSC39470; SCH4831) is a glucocorticoid steroid and an approved medication with moderate anti-inflammatory and immunosuppressive activities. Betamethasone has shown the inflammatory response by the betamethasone-receptor complex modulated the activity of certain genes, altering the production and activity of proteins. Betamethasone has been reported to inhibit the expression of these enzymes results in reduced production of such inflammatory mediators as prostaglandins, leukotrienes and nitric oxide.
ln Vitro |
In L929 cells, betamethasone (0.1–1 μM; 12 h) increases gene expression[4]. The apoptosis of CEM C7 T-cells is induced by betamethasone (0.1–1 μM; 48 h)[4].
|
---|---|
ln Vivo |
Because betamethasone (0.48 mg; IVGT for 48 hours) reduces cerebral vasodilatation, it lessens the increase in CBF caused by hypercapnia[1]. Topical administration of betamethasone (0.05 ml; 1 mg/L) lowers activation of NF-κB, elevates TNFα and IL-1β, and stimulates the expression of IL-10 in the rats brain, all of which are caused by mechanical allodynia and thermal hyperalgesia induced by spinal nerve transection[2].
|
Animal Protocol |
Animal/Disease Models: Rambouillet-Colombia ewes bred on a single occasion are received hypercapnic challenges[1]
Doses: 0.48 mg Route of Administration: Injected into the fetal jugular vein at a rate of 1 ml/h (10 μg betamethasone/h) and maintained over the next 48 h. Experimental Results: diminished cerebral blood flow (CBF) in all brain regions measured except the hippocampus after 24 h of infusion. The reduction in CBF was diminished to about 25-30 % after 48 h of infusion. |
References |
[1]. Schwab M, et, al. Effects of betamethasone administration to the fetal sheep in late gestation on fetal cerebral blood flow. J Physiol. 2000 Nov 1;528(Pt 3):619-32.
[2]. Xie W, et, al. Betamethasone affects cerebral expressions of NF-kappaB and cytokines that correlate with pain behavior in a rat model of neuropathy. Ann Clin Lab Sci. Winter 2006;36(1):39-46. [3]. Kubin ME, et, al. Clinical Efficiency of Topical Calcipotriol/Betamethasone Treatment in Psoriasis Relies on Suppression of the Inflammatory TNFα - IL-23 - IL-17 Axis. Acta Derm Venereol. 2017 Apr 6;97(4):449-455. [4]. Hofmann TH, et, al. Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett. 1998 Dec 28;441(3):441-6. |
Molecular Formula |
C22H29FO5
|
|
---|---|---|
Molecular Weight |
392.46
|
|
CAS # |
378-44-9
|
|
Related CAS # |
Betamethasone disodium phosphate;151-73-5;Betamethasone-d5;Betamethasone dipropionate;5593-20-4;Betamethasone valerate;2152-44-5;Betamethasone hydrochloride;956901-32-9;Betamethasone acetate;987-24-6;Betamethasone-d5-1;2244574-92-1
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
C[C@@]12[C@](C[ C@H](C)[C@]2(O)C(CO)=O)([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C1)=O
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5480 mL | 12.7402 mL | 25.4803 mL | |
5 mM | 0.5096 mL | 2.5480 mL | 5.0961 mL | |
10 mM | 0.2548 mL | 1.2740 mL | 2.5480 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.